{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:27:20Z","timestamp":1782516440672,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["ESR-14-10088"],"award-info":[{"award-number":["ESR-14-10088"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and aims<\/jats:title>\n                <jats:p>Cardiovascular outcome trials have documented a strong benefit of sodium glucose cotransporter-2 inhibitors (SGLT2i) on the risk of hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D) with or without established cardiovascular disease or prior history of HF. The mechanisms, however, are not entirely clear. We aimed to evaluate whether treatment with SGLT2i affected cardiac function using impedance cardiography (ICG) in a randomized placebo-controlled trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Thirty-three patients with T2D were randomized to receive blind dapagliflozin 10\u00a0mg or matching placebo for 12-week on top of their ongoing glucose lowering medication regimen. Cardiac function was evaluated by resting ICG at baseline and at the end of the 12-week treatment period. ICG is a non-invasive technology based on the continuous measurement of thoracic electrical conductivity to process a cardiodynamic parameters related to fluid content, blood flow, cardiac function, and circulatory function. We also evaluated changes in glycaemic control, blood pressure, and body weight.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-one patients completed the study, 1 was excluded because ICG data was missing. Patients included in the final analysis were on average 63.4-year-old, with a known diabetes duration of 14.1\u00a0years and a baseline HbA1c of 8.2% (66\u00a0mmol\/mol). 63.3% of patients had established cardiovascular disease (symptomatic or asymptomatic) and 36.7% had microangiopathy, but none had a prior history of HF. After 12\u00a0weeks, patients randomized to dapagliflozin, as compared to those randomized to placebo, showed improvements in HbA1c (\u2212\u20091.2%; 13\u00a0mmol\/mol), systolic blood pressure (\u2212\u20093.7\u00a0mmHg), and body weight (\u2212\u20093.3\u00a0kg). Based on ICG, in both groups, we detected no significant change in parameters of blood flow (stroke volume, cardiac output, cardiac index), systolic function (ejection fraction, acceleration and velocity indexes, systolic time ratio), circulatory function (systemic vascular resistance index), and fluid status (thoracic fluid content) after treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This is the first study exploring cardiac effects of SGLT2i using ICG in T2D. We observed no change in cardiac function parameters estimated by ICG in T2D patients who received dapagliflozin versus placebo for 12\u00a0weeks.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> ClinicalTrial.gov NCT02327039. Registered 30 December 2014<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-019-0910-5","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T12:03:39Z","timestamp":1565784219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial"],"prefix":"10.1186","volume":"18","clinical-trial-number":[{"clinical-trial-number":"nct02327039","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Benedetta Maria","family":"Bonora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saula","family":"Vigili de Kreutzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Avogaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-2097","authenticated-orcid":false,"given":"Gian Paolo","family":"Fadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"key":"910_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","volume":"34","author":"WB Kannel","year":"1974","unstructured":"Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29\u201334.","journal-title":"Am J Cardiol"},{"key":"910_CR2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Sattar N, Eliasson B, Svensson A-M, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633\u201344.","journal-title":"N Engl J Med"},{"key":"910_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","volume":"3","author":"AD Shah","year":"2015","unstructured":"Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015;3:105\u201313.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"910_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ejhf.1170","volume":"20","author":"PM Seferovi\u0107","year":"2018","unstructured":"Seferovi\u0107 PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:853\u201372.","journal-title":"Eur J Heart Fail"},{"key":"910_CR5","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","volume":"29","author":"MR MacDonald","year":"2008","unstructured":"MacDonald MR, Petrie MC, Varyani F, \u00d6stergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377\u201385.","journal-title":"Eur Heart J"},{"key":"910_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/ejhf.679","volume":"19","author":"G Targher","year":"2017","unstructured":"Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic PM, et al. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:54\u201365.","journal-title":"Eur J Heart Fail"},{"issue":"480\u2013486","key":"910_CR7","first-page":"e3","volume":"162","author":"JR Kapoor","year":"2011","unstructured":"Kapoor JR, Fonarow GC, Zhao X, Kapoor R, Hernandez AF, Heidenreich PA. Diabetes, quality of care, and in-hospital outcomes in patients hospitalized with heart failure. Am Heart J. 2011;162(480\u2013486):e3.","journal-title":"Am Heart J"},{"key":"910_CR8","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.2337\/dc18-0831","volume":"41","author":"YJ Cheng","year":"2018","unstructured":"Cheng YJ, Imperatore G, Geiss LS, Saydah SH, Albright AL, Ali MK, et al. Trends and disparities in cardiovascular mortality among U.S. adults with and without self-reported diabetes, 1988\u20132015. Diabetes Care. 2018;41:2306\u201315.","journal-title":"Diabetes Care."},{"key":"910_CR9","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","volume":"61","author":"MC Thomas","year":"2018","unstructured":"Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61:2098\u2013107.","journal-title":"Diabetologia"},{"key":"910_CR10","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"910_CR11","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"910_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"910_CR13","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"910_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","volume":"5","author":"KI Birkeland","year":"2017","unstructured":"Birkeland KI, J\u00f8rgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017;5:709\u201317.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"910_CR15","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1161\/CIRCULATIONAHA.118.039177","volume":"139","author":"P Elisabetta","year":"2019","unstructured":"Elisabetta P, Ajinkya P, Mehdi N, Anouk D-L, et al. Empagliflozin and the Risk of heart failure hospitalization in routine clinical care: a first analysis from the empagliflozin comparative Effectiveness and Safety (EMPRISE) Study. Circulation. 2019;139:2822\u201330.","journal-title":"Circulation."},{"key":"910_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower Risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation. 2017;136:249\u201359.","journal-title":"Circulation"},{"key":"910_CR17","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108\u201317.","journal-title":"Diabetologia"},{"key":"910_CR18","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1053\/j.jvca.2013.12.026","volume":"28","author":"J-L Fellahi","year":"2014","unstructured":"Fellahi J-L, Fischer M-O. Electrical bioimpedance cardiography: an old technology with new hopes for the future. J Cardiothorac Vasc Anesth. 2014;28:755\u201360.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"910_CR19","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/oxfordjournals.eurheartj.a015464","volume":"18","author":"HH Woltjer","year":"1997","unstructured":"Woltjer HH, Bogaard HJ, De Vries PMJM. The technique of impedance cardiography. Eur Heart J. 1997;18:1396\u2013403.","journal-title":"Eur Heart J"},{"key":"910_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12933-017-0529-3","volume":"16","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Bonora BM, Zatti G, Vitturi N, Iori E, Marescotti MC, et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017;16:42.","journal-title":"Cardiovasc Diabetol."},{"key":"910_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"2009","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group. A new equation to estimate glomerular filtration rate development and comparison of a new equation to estimate GFR. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"910_CR22","first-page":"786","volume":"98","author":"Early TDRSRG","year":"2013","unstructured":"Early TDRSRG. Grading diabetic retinopathy from stereoscopic color fundus photographs\u2014an extension of the modified Airlie house classification. Ophthalmology. 2013;98:786\u2013806.","journal-title":"Ophthalmology."},{"key":"910_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the american society of echocardiography and the european association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233\u201371.","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"910_CR24","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","volume":"17","author":"SF Nagueh","year":"2016","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, Byrd BF III, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the american society of echocardiography and the european association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2016;17:1321\u201360.","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"910_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jez082","author":"T Machino-Ohtsuka","year":"2019","unstructured":"Machino-Ohtsuka T, Seo Y, Ishizu T, Hamada-Harimura Y, Yamamoto M, Sato K, et al. Clinical utility of the 2016 ASE\/EACVI recommendations for the evaluation of left ventricular diastolic function in the stratification of post-discharge prognosis in patients with acute heart failure. Eur Heart J Cardiovasc Imaging. 2019. https:\/\/doi.org\/10.1093\/ehjci\/jez082.","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"910_CR26","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.jacc.2005.12.071","volume":"47","author":"M Packer","year":"2006","unstructured":"Packer M, Abraham WT, Mehra MR, Yancy CW, Lawless CE, Mitchell JE, et al. Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure. J Am Coll Cardiol. 2006;47:2245\u201352.","journal-title":"J Am Coll Cardiol"},{"key":"910_CR27","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3945\/ajcn.110.003582","volume":"93","author":"S Vigili de Kreutzenberg","year":"2011","unstructured":"Vigili de Kreutzenberg S, Fadini GP, Boscari F, Rossi E, Guerra S, Sparacino G, et al. Impaired hemodynamic response to meal intake in insulin-resistant subjects: an impedance cardiography approach. Am J Clin Nutr. 2011;93:926\u201333.","journal-title":"Am J Clin Nutr"},{"key":"910_CR28","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1553-2712.2003.tb00054.x","volume":"10","author":"RL Summers","year":"2003","unstructured":"Summers RL, Shoemaker WC, Peacock WF, Ander DS, Coleman TG. Bench to bedside: electrophysiologic and clinical principles of noninvasive hemodynamic monitoring using impedance cardiography. Acad Emerg Med. 2003;10:669\u201380.","journal-title":"Acad Emerg Med"},{"key":"910_CR29","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1097\/00003246-198610000-00017","volume":"14","author":"DP Bernstein","year":"1986","unstructured":"Bernstein DP. A new stroke volume equation for thoracic electrical bioimpedance: theory and rationale. Crit Care Med. 1986;14:904\u20139.","journal-title":"Crit Care Med"},{"key":"910_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40885-017-0084-y","volume":"23","author":"R Naz\u00e1rio Le\u00e3o","year":"2017","unstructured":"Naz\u00e1rio Le\u00e3o R, Marques Silva P, Branco L, Fonseca H, Bento B, Alves M, et al. Systolic time ratio measured by impedance cardiography accurately screens left ventricular diastolic dysfunction in patients with arterial hypertension. Clin Hypertens. 2017;23:28.","journal-title":"Clin Hypertens."},{"key":"910_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1053\/j.ajkd.2016.03.410","volume":"68","author":"BA Perkins","year":"2016","unstructured":"Perkins BA, Udell JA, Cherney DZI. No need to sugarcoat the message: is cardiovascular risk reduction from SGLT2 inhibition related to natriuresis? Am J Kidney Dis. 2016;68:349\u201352.","journal-title":"Am J Kidney Dis"},{"issue":"262\u2013275","key":"910_CR32","first-page":"e9","volume":"8","author":"WL Baker","year":"2014","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(262\u2013275):e9.","journal-title":"J Am Soc Hypertens."},{"key":"910_CR33","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, W\u00fcst RCI, Fiolet JWT, Stienen GJM, Coronel R, et al. Empagliflozin decreases myocardial cytoplasmic Na+\u2009through inhibition of the cardiac Na+\/H+\u2009exchanger in rats and rabbits. Diabetologia. 2017;60:568\u201373.","journal-title":"Diabetologia"},{"key":"910_CR34","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia. 2018;61:722\u20136.","journal-title":"Diabetologia"},{"key":"910_CR35","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","volume":"104","author":"T-M Lee","year":"2017","unstructured":"Lee T-M, Chang N-C, Lin S-Z. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298\u2013310.","journal-title":"Free Radic Biol Med."},{"key":"910_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, Li X, Han F, Liu X, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18:15.","journal-title":"Cardiovasc Diabetol."},{"key":"910_CR37","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/jphp.12223","volume":"66","author":"A Tahara","year":"2014","unstructured":"Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol. 2014;66:975\u201387.","journal-title":"J Pharm Pharmacol"},{"key":"910_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","volume":"85","author":"WT Garvey","year":"2018","unstructured":"Garvey WT, Van Gaal L, Leiter LA, Vijapurkar U, List J, Cuddihy R, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018;85:32\u20137.","journal-title":"Metabolism."},{"key":"910_CR39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","volume":"17","author":"T Sato","year":"2018","unstructured":"Sato T, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17:6.","journal-title":"Cardiovasc Diabetol."},{"key":"910_CR40","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME Trial: a \u201cThrifty Substrate\u201d hypothesis. Diabetes Care. 2016;39:1108\u201314.","journal-title":"Diabetes Care"},{"key":"910_CR41","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/dom.13670","volume":"21","author":"CJ Bailey","year":"2019","unstructured":"Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab. 2019;21:1291\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"910_CR42","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853\u201362.","journal-title":"Diabetes Obes Metab"},{"key":"910_CR43","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","volume":"16","author":"A Solini","year":"2017","unstructured":"Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol. 2017;16:138.","journal-title":"Cardiovasc Diabetol."},{"key":"910_CR44","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/dom.12572","volume":"17","author":"R Chilton","year":"2015","unstructured":"Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17:1180\u201393.","journal-title":"Diabetes Obes Metab"},{"key":"910_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.lfs.2018.01.032","volume":"197","author":"H Li","year":"2018","unstructured":"Li H, Shin SE, Seo MS, An JR, Choi I-W, Jung W-K, et al. The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels. Life Sci. 2018;197:46\u201355.","journal-title":"Life Sci"},{"key":"910_CR46","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","volume":"3","author":"S Verma","year":"2018","unstructured":"Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H, et al. Empagliflozin Increases cardiac energy\u00a0production\u00a0in diabetes: novel translational insights into the heart failure benefits\u00a0of\u00a0SGLT2 inhibitors. JACC Basic to Transl Sci. 2018;3:575\u201387.","journal-title":"JACC Basic to Transl Sci."},{"key":"910_CR47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-018-0717-9","volume":"17","author":"D Matsutani","year":"2018","unstructured":"Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 2018;17:73.","journal-title":"Cardiovasc Diabetol."},{"key":"910_CR48","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","volume":"17","author":"F Soga","year":"2018","unstructured":"Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17:132.","journal-title":"Cardiovasc Diabetol."},{"key":"910_CR49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12933-016-0419-0","volume":"15","author":"JSS Singh","year":"2016","unstructured":"Singh JSS, Fathi A, Vickneson K, Mordi I, Mohan M, Houston JG, et al. Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol. 2016;15:97.","journal-title":"Cardiovasc Diabetol."},{"key":"910_CR50","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12933-017-0615-6","volume":"16","author":"A Natali","year":"2017","unstructured":"Natali A, Nesti L, Fabiani I, Calogero E, Di Bello V. Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. Cardiovasc Diabetol. 2017;16:130.","journal-title":"Cardiovasc Diabetol."},{"issue":"139","key":"910_CR51","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","volume":"28","author":"ET Kato","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;28(139):2528\u201336.","journal-title":"Circulation"},{"key":"910_CR52","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1186\/s13054-014-0603-0","volume":"18","author":"ME Blohm","year":"2014","unstructured":"Blohm ME, Obrecht D, Hartwich J, Mueller GC, Kersten JF, Weil J, et al. Impedance cardiography (electrical velocimetry) and transthoracic echocardiography for non-invasive cardiac output monitoring in pediatric intensive care patients: a prospective single-center observational study. Crit Care. 2014;18:603.","journal-title":"Crit Care"},{"key":"910_CR53","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/bja\/aei224","volume":"95","author":"C Schmidt","year":"2005","unstructured":"Schmidt C, Theilmeier G, Van Aken H, Korsmeier P, Wirtz SP, Berendes E, et al. Comparison of electrical velocimetry and transoesophageal Doppler echocardiography for measuring stroke volume and cardiac output. Br J Anaesth. 2005;95:603\u201310.","journal-title":"Br J Anaesth"},{"key":"910_CR54","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10558-008-9062-z","volume":"8","author":"H Zhang","year":"2008","unstructured":"Zhang H, Li JK. Noninvasive monitoring of transient cardiac changes with impedance cardiography. Cardiovasc Eng. 2008;8:225\u201331.","journal-title":"Cardiovasc Eng"},{"key":"910_CR55","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4037\/ajcc2017488","volume":"26","author":"M Borzage","year":"2017","unstructured":"Borzage M, Heidari K, Chavez T, Seri I, Wood JC, Bl\u00fcml S. Measuring stroke volume: impedance cardiography vs phase-contrast magnetic resonance imaging. Am J Crit Care. 2017;26:408\u201315.","journal-title":"Am J Crit Care"},{"key":"910_CR56","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ijcard.2008.11.201","volume":"143","author":"AG Kieback","year":"2010","unstructured":"Kieback AG, Borges AC, Schink T, Baumann G, Laule M. Impedance cardiography versus invasive measurements of stroke volume index in patients with chronic heart failure. Int J Cardiol. 2010;143:211\u201323.","journal-title":"Int J Cardiol"},{"key":"910_CR57","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.2169\/internalmedicine.55.6367","volume":"55","author":"S Hirose","year":"2016","unstructured":"Hirose S, Nakajima S, Iwahashi Y, Seo A, Takahashi T, Tamori Y. Impact of the 8-week administration of tofogliflozin for glycemic control and body composition in japanese patients with type 2 diabetes mellitus. Intern Med. 2016;55:3239\u201345.","journal-title":"Intern Med"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0910-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-019-0910-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0910-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:15:06Z","timestamp":1628612106000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0910-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["910"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0910-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,14]]},"assertion":[{"value":"13 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethical Committee of the University Hospital of Padova (No. 3302\/AO\/14). All participants signed a written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"B.M.B. received lecture or advisory board fees from Astra Zeneca, Eli Lilly, Boehringer Ingelheim, Novo Nordisk and Novartis, G.P.F. received grant support, lecture fees, or advisory board fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi, Genzyme, Abbott, Novartis, and Merck Sharp & Dohme. A.A. received research grants, lecture fees, or advisory board fees from Merck Sharp & Dome, AstraZeneca, Novartis, Boeringher Ingelheim, Sanofi, Mediolanum, Janssen, Novo Nordisk, Eli Lilly, Servier, and Takeda. The remaining authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}